普利制药(300630) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 70.63% to CNY 85,945,705.09 for the reporting period[9] - Operating revenue for the period reached CNY 256,663,287.11, reflecting a growth of 69.46% year-on-year[9] - Basic earnings per share rose by 12.73% to CNY 0.31 for the reporting period[9] - The company reported a net profit excluding non-recurring gains and losses of CNY 82,921,081.09, up 64.74% year-on-year[9] - Total operating revenue for the third quarter reached ¥256,663,287.11, a significant increase from ¥151,461,093.42 in the same period last year, representing a growth of approximately 69.3%[69] - The net profit for the current period reached ¥85,945,705.09, up 70% from ¥50,369,635.87 in the same period last year[76] - The total profit for the current period was ¥88,747,848.97, compared to ¥53,469,635.87 in the previous period, indicating strong financial performance[76] - Net profit for the current period was ¥206,030,166.90, compared to ¥121,157,505.05 in the previous period, reflecting an increase of approximately 70.2%[89] Assets and Liabilities - Total assets increased by 27.96% to CNY 1,419,086,124.85 compared to the end of the previous year[9] - The total net assets attributable to shareholders increased by 18.96% to CNY 1,050,697,301.94 compared to the end of the previous year[9] - The company's total liabilities increased to CNY 368,388,822.91 as of September 30, 2019, compared to CNY 225,703,139.61 at the end of 2018, reflecting a growth of approximately 63.1%[55] - The non-current assets reached CNY 947,129,996.84, up from CNY 669,660,404.66, which is an increase of around 41.5%[52] - The company's total assets increased to ¥1,353,006,329.69 from ¥1,097,022,382.69, marking a growth of about 23.3%[68] Cash Flow - The net cash flow from operating activities decreased by 49.92% to CNY 74,026,431.15 compared to the same period last year[9] - Cash inflow from operating activities was CNY 591,232,578.26, an increase from CNY 375,937,937.30 in the prior period[102] - Cash outflow for purchasing fixed assets and intangible assets was CNY 266,164,416.48, compared to CNY 336,008,137.92 in the previous period[108] - Net cash flow from investing activities was CNY -182,786,637.41, worsening from CNY -102,869,774.08 in the prior year[110] - Cash inflow from financing activities was CNY 155,050,432.15, significantly higher than CNY 19,600,000.00 in the previous period[108] Research and Development - Research and development expenses increased by 35.98% to ¥112,977,475.88, indicating higher investment in R&D[25] - Research and development expenses for the quarter were ¥40,575,415.23, compared to ¥24,337,511.63 in the previous year, reflecting a rise of approximately 66.8%[69] - Research and development expenses increased significantly to ¥50,459,541.52, compared to ¥19,592,684.98 in the previous period, reflecting a focus on innovation[79] - Research and development expenses increased to ¥112,977,475.88 from ¥83,082,097.49, marking a growth of around 36%[86] Shareholder Commitments - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its stock listing, ensuring stability in shareholding[33] - The company reported that shareholders are restricted from transferring more than 25% of their shares annually during their tenure[33] - The company has maintained compliance with all commitments made during its initial public offering[33] - The company has ensured that its commitments remain effective regardless of changes in the positions or departures of its executives[33] Government Support - Government subsidies recognized in the current period amounted to CNY 7,811,732.50[9] - Other income surged by 247.31% to ¥7,811,732.50, primarily due to increased government grants[28] Operational Efficiency - The weighted average return on equity was 8.23%, an increase of 0.53% compared to the previous year[9] - The company reported a significant increase in cash received from operating activities, indicating improved operational efficiency[105] - The operating profit for the current period was ¥88,972,587.95, up from ¥53,462,669.87 in the previous period, showcasing improved operational efficiency[76] Inventory and Receivables - Accounts receivable increased by 68.90% to ¥36,901,926.62, reflecting an increase in received notes[25] - Inventory rose by 37.09% to ¥97,551,629.60, attributed to increased production materials[25] - Accounts receivable rose to CNY 223,961,161.03 from CNY 136,998,595.93, marking an increase of about 63.4%[49] - Inventory levels rose to ¥61,627,846.91 from ¥58,600,316.05, indicating an increase of about 3.5%[59] Borrowings - The company reported a 423.68% increase in short-term borrowings to ¥115,210,000.00, reflecting additional bank loans[25] - Short-term borrowings increased significantly to ¥65,210,000.00 from ¥10,000,000.00, reflecting a rise of 552.1%[62]